Aaron Ondrey
Director of Finance/CFO at ROCKET PHARMACEUTICALS, INC.
Net worth: 1 M $ as of 2024-04-29
Profile
Aaron Ondrey is currently the Chief Financial Officer at Rocket Pharmaceuticals, Inc. He previously worked as the Executive Director-Commercial Finance at Regeneron Pharmaceuticals, Inc. from 2010 to 2018.
Additionally, he served as the Chief Financial Officer & SVP-Financial Planning at Mirati Therapeutics, Inc. from 2022 to 2024.
Mr. Ondrey obtained his undergraduate degree from Case Western Reserve University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-31 | 46,781 ( 0.05% ) | 1 M $ | 2024-04-29 |
Aaron Ondrey active positions
| Companies | Position | Start |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Director of Finance/CFO | 2024-03-25 |
Former positions of Aaron Ondrey
| Companies | Position | End |
|---|---|---|
| MIRATI THERAPEUTICS | Director of Finance/CFO | 2024-01-22 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2018-10-31 |
Training of Aaron Ondrey
| Case Western Reserve University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Aaron Ondrey
